Acquisitions:

1. Marksans Pharma to acquire QliniQ to expand presence in European pharma markets.
2. Alivira Animal Health Limited has signed a binding agreement to acquire 100% of Italy-based BioForLife Italia S.r.l. (BFL) for approximately Rs. 188 crores (~US$19.7 Million).
3. Sun Pharma acquires 100% outstanding shares of Innovcare Lifesciences for Rs. 271 Crore(~US$ 28.4 Million).
4. Incyte to buy bleeding disorder biotech Vega Therapeutics in US$1.25 Billion upfront deal.
5. Zymeworks to acquire Theravance in US$929 Million deal.
6. Ipsen to buy blood cancer company Kartos Therapeutics for US$450 Million upfront.
7. ResMed Acquires Noctrix Health in US$340 Million Deal for Sleep Therapy Expansion.

Licensing:

1. Serum Institute of India to manufacture Oxford Ebola vaccine backed by US$8.6 Million CEPI Funding.
2. Yoginii Wellness partners with Panacea Biotec to expand portfolio.
3. Shilpa Medicare and Gate2Brain sign strategic equity partnership to advance brain cancer therapy.
4. Lupin partners with LABORATORIOS ERN to launch Luforbec in Spain.
5. Ipca Labs announces global licensing collaboration with Bhami’s Research Laboratory for monoclonal antibodies.
6. Pfizer signs AI drug discovery license with Chai Discovery.
7. Merck inks US$510 Million biobucks data generation partnership with Protillion.

Investments/Fund Raising:

1. Zumutor Biologics Secures US$7.3 Milllion to Advance Clinical Trials for Cancer Therapy.
2. 4baseCare announces close of Series B round at Rs 128 Crore (~US$ 13.4 Million).
3. Bengaluru-based startup Mykare.ai has raised a total of US$3.2 Million, including an additional US$1 Million in its latest funding round.
4. Immuneel Therapeutics, a Bengaluru-based cell and gene therapy startup, has announced the successful close of its Rs 100 crore plus (~US$ 10.48 Million) Series B financing.
5. Hoola Health, formerly known as BabyMD, India’s first holistic paediatric healthcare brand, has raised $5 Million in funding, led by Peak XV’s Surge.

1. New Client Win: Aagami Selected to Lead Outlicensing for Key Biosimilars in Japan and South Korea.
2. New Project Win: Aagami Secures Global Strategic Advisory Mandate from existing Client for Phase 3-Ready Cardiovascular Biologic.
3. New Project Win from Existing Client: Aagami Wins New Project from French Biotech Client.
4. Multiple Projects from Existing Clients: US Innovators bringing Confluence of Portable MRI, Robotics & AI in Physician Office.
5. Aagami Founder Dinesh Jain successfully completed BIO Internation Convention (Jun 22-25|San Diego) with more than 40 one-on-one strategic meetings with decision makers.
6. Akshay Bavaria, Associate Director to attend Asia Bio Partnering 2026 (September 1-2| Singapore). Partnering calendar opens August 4, 2026.

For Partnering/Licensing/ Co-development:

1. Dental gel (Marketed in the US & approved in EU) for Prevention & Treatment of Periodontitis, Gingivitis, & Caries. Featured in WSJ, FOX, NBC, ABC, GQ. Already a profit-making product. Licensing available.
2. Seeking Co-development Partner/Investor for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach). By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may also be obtained. 
3. Seeking Co-development/Licensing Partner: Phase 2 completed injectable drug for smoking cessation, with no side effect. Nature derived ingredients.
4. Seeking Co-development/Out-Licensing: Phase 3 stage small molecule first-in-class eye drop to treat pre-surgical cataract (typically for patients 40 to 72 years of age).
5. Available for Licensing/Co-development: Biosimilars such as Adalimumab, Rituximab, & Infliximab with ~2028 market launch timeline.
6. Seeking Partnering/Co-development : Uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. Lead asset (Phase 2) and platform, both available for licensing.
7. Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too. 
8. Seeking Licensing / Co-development / Platform Partnering: FDA-validated Ionic Liquid (IL) enabled drug delivery platform addressing solubility, permeability, and bioavailability challenges. Enables non-invasive systemic delivery via transdermal and oral routes, including peptides and nucleic acids. Clinically validated with an FDA-approved IL-enabled product and demonstrated ~6× improvement in oral bioavailability (e.g., Semaglutide). Platform licensing, molecule-specific licensing, and joint R&D collaborations available. Email us about your challenging molecules at action@aagami.com

For Acquisition:

1. [URGENT] Lucrative (Less than $500K) Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic. Few discussions already ongoing. 2 Bids under evaluation.
2. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology for Next-generation biologics, its product candidates, data package of ~20 drug candidates, IP, NOL and Federal benefits etc.
3. A High Multiple ROI by acquiring small molecule clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready). Low cost and quicker to market vs. Gene Therapy. Their previous asset was acquired for US$400 million.

For Investment:

1. High ROI Opportunity to Invest (Series C) in U.S.based medtech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market for 4 years). Exit via an IPO, strategic M&A, or private equity buyout.
2. Seeking Investment (US$ ~3.76 Million raised in 2026): Join Investors such as BIRAC in uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. The funds will be used to progress the pipeline to the out-licensing stage.
3. High ROI Opportunity to Invest in another U.S. (California) based medtech revolutionizing medical imaging for Brain and Head (US FDA cleared). Exit via an IPO, strategic M&A, or private equity buyout.